Video

Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form

Author(s):

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form. That is starting to change as more therapies and medications work their way through the regulatory approval process.

Professor Ayman Tourbah from the University Hospital of Reims in France discussed what can be done to help level the playing field in the treatment of this form of the disease during the ECTRIMS conference in Barcelona.

While there are considerably more treatment options available for relapsing multiple sclerosis there is considerable research being conducted to help patients with primary progressive multiple sclerosis.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.